Navigation Links
WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology

SHANGHAI, July 23 /PRNewswire-Asia/ - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Dr. Chi-Chung Chan has been appointed as Vice President of Pharmacology. He will report directly to Dr. Shuhui Chen, Chief Scientific Officer.

(Logo: )

Prior to joining WuXi, Dr. Chi-Chung Chan worked at Merck & Co. for 26 years in scientific positions of increasing responsibility. At Merck, he led pharmacology research efforts in inflammation and pain, allergic diseases, cardiovascular diseases, respiratory diseases and, most recently, diabetes and obesity. Dr. Chan obtained a Ph.D. in Pharmacology from the University of Ottawa and a B.S. degree in Biology from Chinese University of Hong Kong.

"I am pleased to welcome Chi-Chung on board as we continue to develop our drug discovery capabilities in pharmacology," said Dr. Ge Li, Chairman and Chief Executive Officer. "WuXi is committed to building a world-class scientific management team with extensive experience in a broad range of scientific disciplines to meet the needs of our customers."

    For more information, please contact:

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048

     Stephanie Liu (for the media)
     Associate Director of Corporate Communications Department
     Tel:   +86-21-5046-4362


SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007
2. WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award
3. WuXi PharmaTech Announces Third Quarter 2007 Results
4. WestChina-Frontier PharmaTech Awarded Full AAALAC Accreditation
5. WuXi PharmaTech (NYSE: WX) Mourns the Tragic Loss of Its Independent Director Shawn Wang
6. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
7. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
8. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
9. Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars
10. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
11. WuXi PharmaTech 2007 Annual Report Available Online
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: